Cancer of the nasopharynx

Critical Reviews in Oncology/Hematology

Volumn 45, Issue 2, 2003, Pages 199-214

  Licitra, Lisa ^a   Bernier, Jacques ^b,g   Cvitkovic, Esteban ^c,h   Grandi, Cesare ^d   Spinazzé, Silvia ^a,i   Bruzzi, Paolo ^e   Gatta, Gemma ^a   Molinari, Roberto ^a,f  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^c CAC Cvitkovic/Associes Consultants   (France)

^d SANTA CHIARA HOSPITAL   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^g UNIVERSITY OF GENEVA   (Switzerland)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ Aosta Hospital   (Italy)

Author keywords

Chemotherapy; Nasopharynx; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BONE DISEASE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; HISTOLOGY; HUMAN; LYMPH NODE METASTASIS; LYMPHOMA; MUSCLE DISEASE; NASOPHARYNX; NASOPHARYNX CANCER; NEUROLOGICAL COMPLICATION; PROGNOSIS; SEROLOGY; SQUAMOUS CELL CARCINOMA; SYMPTOM; TOOTH DISEASE; XEROSTOMIA;

EID: 0037323297     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00210-4     Document Type: Review

References (108)

1. Parkin DM, Muir CS, Whelan SL, Ferlay J, Raymond L, Young J. Cancer incidence in five continents. Lyon: International Agency for Research on cancer. Vol. VII, IARC Scient Publ No 120; 1997.
2. Ferlay J., Bray F., Pisani P., Parkin D.M. Cancer incidence, mortality and prevalence worldwide, version 1.0. 2001;IARC Press, Lyon. IARC Cancer Base No 5.
3. Micheli A, Francisci S, Krogh V, Rossi AG, Crosignani P. Cancer prevalence in Italian cancer registry areas: the ITAPREVAL study. ITAPREVAL Working Group. Tumori 1999;85:309-69.
4. Berrino F, Capocaccia R, Esteve J, editors. Survival of cancer patients in Europe. The EUROCARE-II Study. Lyon: International Agency for Research on Cancer. IARC Scient Publ No 151; 1999.
5. Jiong L., Berrino F., Coebergh J.W. Variation in survival for adults with nasopharyngeal cancer in Europe, 1978-1989. EUROCARE Working Group. Eur. J. Cancer. 34:1998;2162-2166.
6. Coleman M.P., Babb P., Damiecki P. Cancer survival trends in England and Wales, 1971-1995: deprivation and NHS region. Studies in medical and population subjects No. 61. 1999;The Stationary Office Book, London.
7. WHO (World Health Organization). International histological classification of tumours. Histological typing of tumours of the upper respiratory tract and ear (2nd ed.). Springer, 1991.
8. Fritz A., Percy C., Jack A., Shanmugaratnam K., Sobin L., Parkin D.M., et al. ICD-O (International Classification of Diseases for Oncology). 3rd ed. 2000;World Health Organization, Geneva.
9. Simons M.J., Wee G.B., Goh E.H., Chan S.H., Shanmugaratnam K., Day N.E., et al. Immunogenetic aspects of nasopharyngeal carcinoma. IV. Increased risk in Chinese of nasopharyngeal carcinoma associated with a Chinese-related HLA profile (A2, Singapore 2). J. Natl. Cancer Inst. 57:1976;977-980.
10. Liebowitz D. Nasopharyngeal carcinoma: the Epstein-Barr virus association. Semin. Oncol. 21:1994;376-381.
11. Lu Q.L., Elia G., Lucas S., Thomas J.A. Bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int. J. Cancer. 53:1993;29-35.
12. Porter M.J., Field J.K., Lee J.C., Leung S.F., Lo D., van Hasselt C.A. Detection of the tumour suppressor gene p53 in nasopharyngeal carcinoma in Hong Kong Chinese. Anticancer Res. 14:1994;1357-1360.
13. Huang D.P., Lo K.W., van Hasselt C.A., Woo J.K., Choi P.H., Leung S.F., et al. A region of homozygous deletion on chromosome 9p21-22 in primary nasopharyngeal carcinoma. Cancer Res. 54:1994;4003-4006.
14. Lo K.W., Huang D.P., Lau K.M. p16 gene alterations in nasopharyngeal carcinoma. Cancer Res. 55:1995;2039-2043.
15. Fan C.S., Wong N., Leung S.F., To K.F., Lo K.W., Lee S.W., et al. Frequent c-myc and Int-2 overrepresentations in nasopharyngeal carcinoma. Hum. Pathol. 31:2000;169-178.
16. Yazici H., Altun M., Alatli C., Dogan O., Dalay N. c-erbB-2 gene amplification in nasopharyngeal carcinoma. Cancer Invest. 18:2000;6-10.
17. Chang J.T., Liao C.T., Jung S.M., Wang T.C., See L.C., Cheng A.J. Telomerase activity is frequently found in metaplastic and malignant human nasopharyngeal tissues. Br. J. Cancer. 82:2000;1946-1951.
18. Hording U., Nielsen H.W., Daugaard S., Albeck H. Human papillomavirus types 11 and 16 detected in nasopharyngeal carcinomas by the polymerase chain reaction. Laryngoscope. 104:1994;99-102.
19. Weiland L.H. Nasopharyngeal carcinoma. Barnes L. Surgical pathology of the head and neck. 1:1985;453-466 Marcel Deckker, New York.
20. Moss T.W. The nasopharynx. Moss T.W., Cox J.D. Radiation oncology: rationale, technique, results. 1989;189-214 CV Mosby Company, St. Louis.
21. Tang S.G., Lin F.J., Chen M.S., Liaw C.C., Leung W.M., Hong J.H. Prognostic factors of nasopharyngeal carcinoma: a multivariate analysis. Int. J. Radiat. Oncol. Biol. Phys. 19:1990;1143-1149.
22. Ozyar E., Yildiz F., Akyol F.H., Atahan I.L. Comparison of AJCC 1988 and 1997 classifications for nasopharyngeal carcinoma. American Joint Committee on Cancer. Int. J. Radiat. Oncol. Biol. Phys. 44:1999;1079-1087.
23. Lee A.W., Foo W., Law S.C., Poon Y.F., Sk O., Tung S.Y., et al. Staging of nasopharyngeal carcinoma: from Ho's to the new UICC system. Int. J. Cancer. 84:1999;179-187.
24. Heng D.M., Wee J., Fong K.W., Lian L.G., Sethi V.K., Chua E.T., et al. Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma. Cancer. 86:1999;1912-1920.
25. Sobin L.H., Wittekind C. UICC (International Union Against Cancer). TNM classification of malignant tumours. 5th ed. 1997;Wiley-Liss, New York, Chichester, Weinheim, Brisbane, Singapore, Toronto.
26. Cheung Y.K., Sham J., Cheung Y.L., Chan F.L. Evaluation of skull base erosion in nasopharyngeal carcinoma: comparison of plain radiography and computed tomography. Oncology. 51:1994;42-46.
27. Sham J.S., Cheung Y.K., Choy D., Chan F.L., Leong L. Nasopharyngeal carcinoma: CT evaluation of patterns of tumor spread. AJNR. Am. J. Neuroradiol. 12:1991;265-270.
28. Chong V.F., Fan Y.F. Skull base erosion in nasopharyngeal carcinoma: detection by CT and MRI. Clin. Radiol. 51:1996;625-631.
29. Olmi P., Fallai C., Colagrande S., Giannardi G. Staging and follow-up of nasopharyngeal carcinoma: magnetic resonance imaging versus computerized tomography. Int. J. Radiat. Oncol. Biol. Phys. 32:1995;795-800.
30. Kao C.H., ChangLai S.P., Chieng P.U., Yen R.F., Yen T.C. Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with 18-fluoro-2-deoxyglucose positron emission tomography and comparison with computed tomography. J. Clin. Oncol. 16:1998;3550-3555.
31. Lo Y.M., Chan L.Y., Lo K.W., Leung S.F., Zhang J., Chan A.T., et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 59:1999;1188-1191.
32. Mathew A., Cheng H.M., Sam C.K., Joab I., Prasad U., Cochet C. A high incidence of serum IgG antibodies to the Epstein-Barr virus replication activator protein in nasopharyngeal carcinoma. Cancer Immunol. Immunother. 38:1994;68-70.
33. Joab I., Triki H., de Saint M., Perricaudet M., Nicolas J.C. Detection of anti-Epstein-Barr virus trans-activator (ZEBRA) antibodies in sera from patients with human immunodeficiency virus. J. Infect. Dis. 163:1991;53-56.
34. Perez C.A., Devineni V.R., Marcial-Vega V., Marks J.E., Simpson J.R., Kucik N. Carcinoma of the nasopharynx: factors affecting prognosis. Int. J. Radiat. Oncol. Biol. Phys. 23:1992;271-280.
35. Mendenhall W.M., Million R.R., Mancuso A.A., Stringer S.P. Nasopharynx. Million R.R., Cassisi N.J. Management of head and neck cancer: a multidisciplinary approach. 2nd ed. 1994;599-626 Lippincott Company, Philadelphia.
36. Kwong D., Sham J., Choy D. The effect of loco-regional control on distant metastatic dissemination in carcinoma of the nasopharynx: an analysis of 1301 patients. Int. J. Radiat. Oncol. Biol. Phys. 30:1994;1029-1036.
37. Ahmad A., Stefani S. Distant metastases of nasopharyngeal carcinoma: a study of 256 male patients. J. Surg. Oncol. 33:1986;194-197.
38. Cvitkovic E., Bachouchi M., Boussen H., Busson P., Rousselet G., Mahjoubi R., et al. Leukemoid reaction, bone marrow invasion, fever of unknown origin, and metastatic pattern in the natural history of advanced undifferentiated carcinoma of nasopharyngeal type: a review of 255 consecutive cases. J. Clin. Oncol. 11:1993;2434-2442.
39. Micheau C., Boussen H., Klijanienko J., Cvitkovic E., Stosic S., Schwaab G., et al. Bone marrow biopsies in patients with undifferentiated carcinoma of the nasopharyngeal type. Cancer. 60:1987;2459-2464.
40. Mesic J.B., Fletcher G.H., Goepfert H. Megavoltage irradiation of epithelial tumors of the nasopharynx. Int. J. Radiat. Oncol. Biol. Phys. 7:1981;447-453.
41. Kaasa S., Kragh-Jensen E., Bjordal K., Lund E., Evensen J.F., Vermund H., et al. Prognostic factors in patients with nasopharyngeal carcinoma. Acta Oncol. 32:1993;531-536.
42. Leung S.F., Teo P.M., Foo W.W., van Hasselt C.A., Shiu W.C., Ting C.L., et al. Pretreatment neck node biopsy, distant metastases, and survival in nasopharyngeal carcinoma. Head Neck. 15:1993;296-299.
43. Sanguineti G., Geara F.B., Garden A.S., Tucker S.L., Ang K.K., Morrison W.H., et al. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. Int. J. Radiat. Oncol. Biol. Phys. 37:1997;985-996.
44. Roychowdhury D.F., Tseng A., Fu K.K., Weinburg V., Weidner N. New prognostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and C-erbB2 expression. Cancer. 77:1996;1419-1426.
45. Fandi A., Bachouchi M., Azli N., Taamma A., Boussen H., Wibault P., et al. Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J. Clin. Oncol. 18:2000;1324-1330.
46. Gallo O., Bianchi S., Giannini A., Gallina E., Libonati G.A., Fini-Storchi O. Correlations between histopathological and biological findings in nasopharyngeal carcinoma and its prognostic significance. Laryngoscope. 101:1991;487-493.
47. Munck J.N., Cvitkovic E., Piekarski J.D., Benhamou E., Recondo G., Bachouchi M., et al. Computed tomographic density of metastatic lymph nodes as a treatment-related prognostic factor in advanced head and neck cancer. J. Natl. Cancer Inst. 83:1991;569-575.
48. Lin Z.X., Li D.R., Chen Z.J., Zheng M.Z., Shi Y.Y., Lin B.H., et al. What is the significance of nasal involvement in nasopharyngeal carcinoma? Int. J. Radiat. Oncol. Biol. Phys. 45:1999;907-914.
49. Fletcher G.H., Million R. Nasopharynx. Fletcher G.H. Textbook of radiotherapy. 3rd ed. 1980;364-383 Lea and Febiger, Philadelphia.
50. Hoppe R.T., Goffinet D.R., Bagshaw M.A. Carcinoma of the nasopharynx. Eighteen years' experience with megavoltage radiation therapy. Cancer. 37:1976;2605-2612.
51. Lee A.W., Sham J.S., Poon Y.F., Ho J.H. Treatment of stage I nasopharyngeal carcinoma: analysis of the patterns of relapse and the results of withholding elective neck irradiation. Int. J. Radiat. Oncol. Biol. Phys. 17:1989;1183-1190.
52. Lee A.W., Poon Y.F., Foo W., Law S.C., Cheung F.K., Chan D.K., et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int. J. Radiat. Oncol. Biol. Phys. 23:1992;261-270.
53. al-Sarraf M., LeBlanc M., Giri P.G., Fu K.K., Cooper J., Vuong T., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J. Clin. Oncol. 16:1998;1310-1317.
54. Wang C.C. Accelerated hyperfractionation radiation therapy for carcinoma of the nasopharynx. Techniques and results. Cancer. 63:1989;2461-2467.
55. Ang K.K., Peters L.J., Weber R.S., Maor M.H., Morrison W.H., Wendt C.D., et al. Concomitant boost radiotherapy schedules in the treatment of carcinoma of the oropharynx and nasopharynx. Int. J. Radiat. Oncol. Biol. Phys. 19:1990;1339-1345.
56. Lee A.W., Sze W.M., Fowler J.F., Chappell R., Leung S.F., Teo P. Caution on the use of altered fractionation for nasopharyngeal carcinoma. Radiother. Oncol. 52:1999;207-211.
57. Chang J.T., See L.C., Tang S.G., Lee S.P., Wang C.C., Hong J.H. The role of brachytherapy in early-stage nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 36:1996;1019-1024.
58. Teo P.M., Leung S.F., Lee W.Y., Zee B. Intracavitary brachytherapy significantly enhances local control of early T-stage nasopharyngeal carcinoma: the existence of a dose-tumor-control relationship above conventional tumoricidal dose. Int. J. Radiat. Oncol. Biol. Phys. 46:2000;445-458.
59. Cmelak A.J., Cox R.S., Adler J.R., Fee W.E., Goffinet D.R. Radiosurgery for skull base malignancies and nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 37:1997;997-1003.
60. Tate D.J., Adler J.R.J., Chang S.D., Marquez S., Eulau S.M., Fee W.E., et al. Stereotactic radiosurgical boost following radiotherapy in primary nasopharyngeal carcinoma: impact on local control. Int. J. Radiat. Oncol. Biol. Phys. 45:1999;915-921.
61. Altun M., Fandi A., Dupuis O., Cvitkovic E., Krajina Z., Eschwege F. Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects. Int. J. Radiat. Oncol. Biol. Phys. 32:1995;859-877.
62. Azli N., Armand J.P., Rahal M., Wibault P., Boussen H., Eschwege F., et al. Alternating chemo-radiotherapy with cisplatin and 5-fluorouracil plus bleomycin by continuous infusion for locally advanced undifferentiated carcinoma nasopharyngeal type. Eur. J. Cancer. 28A:1992;1792-1797.
63. Azli N., Fandi A., Bachouchi M., Rahal M., Lianes P., Wibault P., et al. Final Report of a Phase II Study of Chemotherapy with Bleomycin, Epirubicin, and Cisplatin for Locally Advanced and Metastatic/Recurrent Undifferentiated Carcinoma of the Nasopharyngeal Type. Cancer J. Sci. Am. 1:1995;222.
64. Dimery I.W., Peters L.J., Goepfert H., Morrison W.H., Byers R.M., Guillory C., et al. Effectiveness of combined induction chemotherapy and radiotherapy in advanced nasopharyngeal carcinoma. J. Clin. Oncol. 11:1993;1919-1928.
65. Hong S., Wu H.G., Chie E.K., Bang Y.J., Heo D.S., Kim K.H., et al. Neoadjuvant chemotherapy and radiation therapy compared with radiation therapy alone in advanced nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 45:1999;901-905.
66. Ho S., Teo P., Kwan W.H., Choi P., Tjong J., Johnson P.J. Staging and IgA VCA titre in patients with nasopharyngeal carcinoma: changes over a 12-year period. Oral Oncol. 34:1998;491-495.
67. VUMCA (Intl NP Cancer Study Group). Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or=N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. International Nasopharynx Cancer Study Group. VUMCA I trial Int. J. Radiat. Oncol. Biol. Phys. 1996; 35:463-469.
68. Chua D.T., Kwong D.L., Sham J.S., Au G.K., Choy D. A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy. Eur. J. Cancer. 36:2000;736-741.
69. Ma J., Mai H.Q., Hong M.H., Min H.Q., Mao Z.D., Cui N.J., et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J. Clin. Oncol. 19:2001;1350-1357.
70. Chan A.T., Teo P.M., Leung T.W., Leung S.F., Lee W.Y., Yeo W., et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 33:1995;569-577.
71. Souhami L., Rabinowits M. Combined treatment in carcinoma of the nasopharynx. Laryngoscope. 98:1988;881-883.
72. al-Sarraf M., Pajak T.F., Cooper J.S., Mohiuddin M., Herskovic A., Ager P.J. Chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma: a radiation therapy oncology group study. J. Clin. Oncol. 8:1990;1342-1351.
73. Tsujii H., Kamada T., Tsuji H., Takamura A., Matsuoka Y., Usubuchi H., et al. Improved results in the treatment of nasopharyngeal carcinoma using combined radiotherapy and chemotherapy. Cancer. 63:1989;1668-1672.
74. Cooper J.S., Lee H., Torrey M., Hochster H. Improved outcome secondary to concurrent chemoradiotherapy for advanced carcinoma of the nasopharynx: preliminary corroboration of the intergroup experience. Int. J. Radiat. Oncol. Biol. Phys. 47:2000;861-866.
75. Teo P.M., Leung S.F., Chan A.T., Leung T.W., Choi P.H., Kwan W.H., et al. Final report of a randomized trial on altered-fractionated radiotherapy in nasopharyngeal carcinoma prematurely terminated by significant increase in neurologic complications. Int. J. Radiat. Oncol. Biol. Phys. 48:2000;1311-1322.
76. Wolden S.L., Steinherz P.G., Kraus D.H., Zelefsky M.J., Pfister D.G., Wollner N. Improved long-term survival with combined modality therapy for pediatric nasopharynx cancer. Int. J. Radiat. Oncol. Biol. Phys. 46:2000;859-864.
77. Rossi A., Molinari R., Boracchi P., Del Vecchio M., Marubini E., Nava M., et al. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J. Clin. Oncol. 6:1988;1401-1410.
78. Tan E.H., Chua E.T., Wee J., Tan T., Fong K.W., Ang P.T., et al. Concurrent chemoradiotherapy followed by adjuvant chemotherapy in Asian patients with nasopharyngeal carcinoma: toxicities and preliminary results. Int. J. Radiat. Oncol. Biol. Phys. 45:1999;597-601.
79. Jelic S., Kovcin V., Milanovic N., Kreacic M., Pendjer I., Jovanovic V., et al. Randomized study of zorubicin versus zorubicin-cisplatin in undifferentiated carcinoma of the nasopharynx (UCNT). Ann. Oncol. 8:1997;739-744.
80. Kwong D.L., Nicholls J., Wei W.I., Chua D.T., Sham J.S., Yuen P.W., et al. The time course of histologic remission after treatment of patients with nasopharyngeal carcinoma. Cancer. 85:1999;1446-1453.
81. Buatti J.M., Friedman W.A., Bova F.J., Mendenhall W.M. Linac radiosurgery for locally recurrent nasopharyngeal carcinoma: rationale and technique. Head Neck. 17:1995;14-19.
82. Goffinet D.R. Treatment of recurrent nasopharyngeal cancer by radiation therapy. Head and neck cancer. 3:1993;455-463 Elsevier Science Excerpta Medica.
83. Pryzant R.M., Wendt C.D., Delclos L., Peters L.J. Re-treatment of nasopharyngeal carcinoma in 53 patients. Int. J. Radiat. Oncol. Biol. Phys. 22:1992;941-947.
84. Wang C.C. Re-irradiation of recurrent nasopharyngeal carcinoma - treatment techniques and results. Int. J. Radiat. Oncol. Biol. Phys. 13:1987;953-956.
85. Lee A.W., Foo W., Law S.C., Poon Y.F., Sze W.M., Sk O., et al. Reirradiation for recurrent nasopharyngeal carcinoma: factors affecting the therapeutic ratio and ways for improvement. Int. J. Radiat. Oncol. Biol. Phys. 38:1997;43-52.
86. Lee A.W., Foo W., Law S.C., Poon Y.F., Sze W.M., Sk O., et al. Recurrent nasopharyngeal carcinoma: the puzzles of long latency. Int. J. Radiat. Oncol. Biol. Phys. 44:1999;149-156.
87. Chang J.T., See L.C., Liao C.T., Ng S.H., Wang C.H., Chen I.H., et al. Locally recurrent nasopharyngeal carcinoma. Radiother. Oncol. 54:2000;135-142.
88. Chua D.T., Sham J.S., Hung K.N., Kwong D.L., Kwong P.W., Leung L.H. Stereotactic radiosurgery as a salvage treatment for locally persistent and recurrent nasopharyngeal carcinoma. Head Neck. 21:1999;620-626.
89. Fee W.E., Roberson J.B., Goffinet D.R. Long-term survival after surgical resection for recurrent nasopharyngeal cancer after radiotherapy failure. Arch. Otolaryngol. Head Neck Surg. 117:1991;1233-1236.
90. Tu G.Y., Hu Y.H., Xu G.Z., Ye M. Salvage surgery for nasopharyngeal carcinoma. Arch. Otolaryngol. Head Neck Surg. 114:1988;328-329.
91. Shu C.H., Shiau C.Y., Chi K.H., Yen S.H., Li W.Y. Salvage surgery for recurrent nasopharyngeal carcinoma in anterior marginal miss after radiotherapy. Otolaryngol. Head Neck Surg. 121:1999;622-626.
92. King W.W., Ku P.K., Mok C.O., Teo P.M. Nasopharyngectomy in the treatment of recurrent nasopharyngeal carcinoma: a twelve-year experience. Head Neck. 22:2000;215-222.
93. Gandia D., Wibault P., Guillot T., Bensmaine A., Armand J.P., Marandas P., et al. Simultaneous chemoradiotherapy as salvage treatment in locoregional recurrences of squamous head and neck cancer. Head Neck. 15:1993;8-15.
94. Choo R., Tannock I. Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx. A review of the Princess Margaret Hospital experience. Cancer. 68:1991;2120-2124.
95. Gebbia V., Zerillo G., Restivo G., Speciale R., Cupido G., Lo B.P., et al. Chemotherapeutic treatment of recurrent and/or metastatic nasopharyngeal carcinoma: a retrospective analysis of 40 cases. Br. J. Cancer. 68:1993;191-194.
96. Chi K.H., Chan W.K., Cooper D.L., Yen S.H., Lin C.Z., Chen K.Y. A phase II study of outpatient chemotherapy with cisplatin, 5-fluorouracil, and leucovorin in nasopharyngeal carcinoma. Cancer. 73:1994;247-252.
97. Hasbini A., Mahjoubi R., Fandi A., Chouaki N., Taamma A., Lianes P., et al. Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type. Ann. Oncol. 10:1999;421-425.
98. Hong R.L., Sheen T.S., Ko J.Y., Hsu M.M., Wang C.C., Ting L.L. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study. Br. J. Cancer. 80:1999;1962-1967.
99. Taamma A., Fandi A., Azli N., Wibault P., Chouaki N., Hasbini A., et al. Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer. 86:1999;1101-1108.
100. Chi K.H., Chan W.K., Chao Y., Wang C.S., Chen S.Y., Shu C.H., et al. Phase II study of paclitaxel therapy for chemotherapy-nalve advanced nasopharyngeal carcinoma (NPC). Proc. ASCO. 16:1997;398a.
101. Tan E.H., Khoo K.S., Wee J., Fong K.W., Lee K.S., Lee K.M., et al. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann. Oncol. 10:1999;235-237.
102. Fountzilas G., Skarlos D., Athanassiades A., Kalogera-Fountzila A., Samantas E., Bacoyiannis C., et al. Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study conducted by the Hellenic Cooperative Oncology Group. Ann. Oncol. 8:1997;451-455.
103. Chang C.C., Chen M.K., Wen Y.S., Lee H.S., Wu H.K., Liu M.T. Effects of radiotherapy for nasopharyngeal carcinoma on the paranasal sinuses: study based on computed tomography scanning. J. Otolaryngol. 29:2000;23-27.
104. Wu C.H., Hsiao T.Y., Ko J.Y., Hsu M.M. Dysphagia after radiotherapy: endoscopic examination of swallowing in patients with nasopharyngeal carcinoma. Ann. Otol. Rhinol. Laryngol. 109:2000;320-325.
105. Kwong D.L., Wei W.I., Sham J.S., Ho W.K., Yuen P.W., Chua D.T., et al. Sensorineural hearing loss in patients treated for nasopharyngeal carcinoma: a prospective study of the effect of radiation and cisplatin treatment. Int. J. Radiat. Oncol. Biol. Phys. 36:1996;281-289.
106. Peters L.J., Harrison M.L., Dimery I.W., Fields R., Goepfert H., Oswald M.J. Acute and late toxicity associated with sequential bleomycin-containing chemotherapy regimens and radiation therapy in the treatment of carcinoma of the nasopharynx. Int. J. Radiat. Oncol. Biol. Phys. 14:1988;623-633.
107. Chen C.L., Hsu M.M. Second primary epithelial malignancy of nasopharynx and nasal cavity after successful curative radiation therapy of nasopharyngeal carcinoma. Hum. Pathol. 31:2000;227-232.
108. Teo P.M., Chan A.T., Leung S.F., Chau R.M., Yu P.K., King W.W., et al. Increased incidence of tongue cancer after primary radiotherapy for nasopharyngeal carcinoma - the possibility of radiation carcinogenesis. Eur. J. Cancer. 35:1999;219-225.